KELUN PHARMA(002422) 格隆汇·2025-05-26 01:18Core Viewpoint - Hubei Kelun Pharmaceutical has received approval for its generic drug, Compound Potassium Hydrogen Phosphate Injection, which is now recognized as the second domestic company to pass the consistency evaluation for this product [1][5]. Group 1: Product Overview - Compound Potassium Hydrogen Phosphate Injection is primarily used as a phosphorus supplement in total parenteral nutrition therapy for patients who need to fast for more than five days due to moderate or major surgeries or other traumas [3]. - The sales of this product exceeded 300 million yuan in 2023, marking a year-on-year growth of 33.55%. In the first two quarters of 2024, sales already surpassed 200 million yuan, with a year-on-year growth rate of 33% [3]. Group 2: Market Competition - A total of 11 companies, including Shijiazhuang Fourth Pharmaceutical and Tianjin Pharmaceutical, hold production licenses for Compound Potassium Hydrogen Phosphate Injection, with Shijiazhuang Fourth Pharmaceutical being the first to pass the evaluation [5]. - There are 30 companies, including Shandong Hualu Pharmaceutical and Chenxin Pharmaceutical, that have submitted applications for the generic version of this product, indicating a competitive market landscape [6]. Group 3: Company Achievements - Since 2025, Kelun Pharmaceutical (including subsidiaries) has had 13 products approved, including Tacrolimus Sustained-Release Capsules and Chloride Injection, with some being the first to pass the evaluation for their respective categories [8].